Investing.com - Financial Markets Worldwide
💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

CytRx's aldoxorubicin shows positive results in early-stage sarcoma study; shares up 5%

Published 11/11/2016, 10:49 AM
CytRx's aldoxorubicin shows positive results in early-stage sarcoma study; shares up 5%
LADX
-
  • Interim data from a Phase 1b/2 study assessing CytRx's (CYTR +4.7%) aldoxorubicin, in combination with the chemo agent ifosamide (together with mesna to mitigate the side effects of ifosamide), for the treatment of patients with advanced sarcomas showed a positive treatment effect. The results were presented at the 2016 Annual Meeting of the Connective Tissue Oncology Society in Lisbon, Portugal.
  • In 36 evaluable patients receiving either 170 mg/m2 (n=7) or 250 mg/m2 (n=29) of aldoxorubicin plus ifosamide/mensa, 39% experienced a partial response (n=14/36) while 58% (n=21/36) had stable disease, implying a disease control rate of 97% (n=35/36). One patient progressed. Median progression-free survival has not been reached.
  • The most common Grade 3 (severe) or Grade 4 (life-threatening) adverse events were neutropenia (71%), anemia (54%), thrombocytopenia (17%) and febrile neutropenia (14%).
  • The trial has been expanded to allow for additional enrollment at the 250 mg/m2 dose. According to ClinicalTrials.gov, the estimated study completion date is December 2018.
  • Aldoxorubicin is a conjugate of the chemo agent doxorubicin and an acid-sensitive linker that binds to circulating albumin. This supposedly drives greater uptake in the tumor which enables higher dosing without the collateral damage to healthy tissue.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.